Charles Schwab Investment Management Inc. boosted its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 4.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 322,596 shares of the company's stock after buying an additional 12,778 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.68% of Axsome Therapeutics worth $28,992,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also bought and sold shares of the company. Northwestern Mutual Wealth Management Co. bought a new stake in Axsome Therapeutics in the second quarter valued at approximately $27,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Axsome Therapeutics in the second quarter valued at approximately $47,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Axsome Therapeutics by 22.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company's stock valued at $156,000 after purchasing an additional 318 shares during the last quarter. Moors & Cabot Inc. bought a new stake in Axsome Therapeutics in the third quarter valued at approximately $200,000. Finally, Whalen Wealth Management Inc. bought a new stake in Axsome Therapeutics in the third quarter valued at approximately $236,000. Hedge funds and other institutional investors own 81.49% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the company. Cantor Fitzgerald restated an "overweight" rating and set a $107.00 target price on shares of Axsome Therapeutics in a report on Monday, September 16th. Royal Bank of Canada upped their target price on Axsome Therapeutics from $130.00 to $131.00 and gave the company an "outperform" rating in a report on Friday, October 4th. HC Wainwright restated a "buy" rating and set a $180.00 target price on shares of Axsome Therapeutics in a report on Monday, November 25th. Wells Fargo & Company assumed coverage on Axsome Therapeutics in a report on Tuesday, September 3rd. They set an "overweight" rating and a $140.00 target price for the company. Finally, Needham & Company LLC restated a "buy" rating and set a $130.00 target price on shares of Axsome Therapeutics in a report on Tuesday, November 12th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $124.93.
View Our Latest Stock Report on AXSM
Insiders Place Their Bets
In other news, Director Mark E. Saad sold 11,016 shares of the firm's stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total value of $1,005,870.96. Following the transaction, the director now directly owns 10,002 shares in the company, valued at $913,282.62. This trade represents a 52.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 22.40% of the stock is owned by insiders.
Axsome Therapeutics Trading Down 1.2 %
Shares of NASDAQ AXSM traded down $1.19 during trading on Thursday, reaching $98.35. The company had a trading volume of 262,995 shares, compared to its average volume of 614,575. Axsome Therapeutics, Inc. has a 12-month low of $64.11 and a 12-month high of $105.00. The business's 50-day moving average is $92.05 and its 200 day moving average is $86.37. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, topping analysts' consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The firm had revenue of $104.76 million for the quarter, compared to analysts' expectations of $98.71 million. During the same period in the prior year, the firm posted ($1.32) earnings per share. On average, sell-side analysts predict that Axsome Therapeutics, Inc. will post -4.58 EPS for the current year.
About Axsome Therapeutics
(
Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Featured Articles
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
